303 related articles for article (PubMed ID: 9036865)
1. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
Maelandsmo GM; Flørenes VA; Hovig E; Oyjord T; Engebraaten O; Holm R; Børresen AL; Fodstad O
Br J Cancer; 1996 Apr; 73(8):909-16. PubMed ID: 8611425
[TBL] [Abstract][Full Text] [Related]
3. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
4. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
5. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
6. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
Ohta M; Berd D; Shimizu M; Nagai H; Cotticelli M-G ; Mastrangelo M; Shields JA; Shields CL; Croce CM; Huebner K
Int J Cancer; 1996 Mar; 65(6):762-7. PubMed ID: 8631588
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
8. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
9. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
[TBL] [Abstract][Full Text] [Related]
10. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
12. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
Matsumura Y; Nishigori C; Yagi T; Imamura S; Takebe H
Arch Dermatol Res; 1998 Apr; 290(4):175-80. PubMed ID: 9617435
[TBL] [Abstract][Full Text] [Related]
13. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
Sonoda Y; Yoshimoto T; Sekiya T
Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
[TBL] [Abstract][Full Text] [Related]
14. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
[TBL] [Abstract][Full Text] [Related]
15. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
[TBL] [Abstract][Full Text] [Related]
16. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma.
Platz A; Ringborg U; Lagerlöf B; Lundqvist E; Sevigny P; Inganäs M
Br J Cancer; 1996 Feb; 73(3):344-8. PubMed ID: 8562340
[TBL] [Abstract][Full Text] [Related]
20. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
